Symbols / CNTX $2.71 -0.37% Context Therapeutics Inc.
CNTX Chart
About
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 248.99M |
| Enterprise Value | 184.03M | Income | -36.12M | Sales | — |
| Book/sh | 0.66 | Cash/sh | 0.72 | Dividend Yield | — |
| Payout | 0.00% | Employees | 15 | IPO | — |
| P/E | — | Forward P/E | -5.86 | PEG | — |
| P/S | — | P/B | 4.12 | P/C | — |
| EV/EBITDA | -4.64 | EV/Sales | — | Quick Ratio | 8.23 |
| Current Ratio | 8.52 | Debt/Eq | 0.18 | LT Debt/Eq | — |
| EPS (ttm) | -0.38 | EPS next Y | -0.46 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-23 16:00 | ROA | -29.79% |
| ROE | -46.39% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 91.88M |
| Shs Float | 42.72M | Short Float | 1.69% | Short Ratio | 1.38 |
| Short Interest | — | 52W High | 3.62 | 52W Low | 0.49 |
| Beta | 1.83 | Avg Volume | 1.41M | Volume | 433.32K |
| Target Price | $6.00 | Recom | Strong_buy | Prev Close | $2.72 |
| Price | $2.71 | Change | -0.37% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.00
Mean price target
2. Current target
$2.71
Latest analyst target
3. DCF / Fair value
$-3.75
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.71
Low
$4.00
High
$9.00
Mean
$6.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-24 | main | D. Boral Capital | Buy → Buy | $9 |
| 2026-03-24 | reit | Guggenheim | Buy → Buy | $5 |
| 2026-03-24 | main | Piper Sandler | Overweight → Overweight | $7 |
| 2025-12-22 | init | Jones Trading | — → Buy | $7 |
| 2025-11-06 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-11-06 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-10-16 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-10-02 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-09-18 | init | Guggenheim | — → Buy | $5 |
| 2025-08-07 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-08-07 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-06-26 | reit | Piper Sandler | Overweight → Overweight | $4 |
| 2025-05-08 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-04-29 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-04-21 | init | William Blair | — → Outperform | — |
| 2025-04-09 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-03-21 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-21 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-01-15 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-01-08 | init | JMP Securities | — → Market Outperform | $4 |
- CNTX Stock Price, Quote & Chart | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill hu, 02 Apr 2026 07
- FDA fast-tracks Context drug for hard-to-treat ovarian cancer - Stock Titan hu, 02 Apr 2026 11
- Context Therapeutics wins FDA fast-track status (CNTX:NASDAQ) - Seeking Alpha hu, 02 Apr 2026 15
- Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation - Yahoo Finance hu, 05 Feb 2026 08
- Context Therapeutics (CNTX) to Release Earnings on Thursday - MarketBeat hu, 12 Mar 2026 07
- We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash Wisely - simplywall.st Fri, 19 Dec 2025 08
- Context Therapeutics Gains FDA Fast Track for CTIM-76 - tipranks.com hu, 02 Apr 2026 12
- Context Therapeutics Reports Full Year 2025 Operating and Financial Results - GlobeNewswire Mon, 23 Mar 2026 07
- FDA grants Fast Track to Context Therapeutics (CNTX) CTIM-76 in platinum-resistant ovarian cancer - Stock Titan hu, 02 Apr 2026 11
- Institutions profited after Context Therapeutics Inc.'s (NASDAQ:CNTX) market cap rose US$14m last week but private equity firms profited the most - Yahoo Finance Wed, 08 Oct 2025 07
- Context Therapeutics Insiders May Regret Not Buying More, Market Cap Hits US$151m - simplywall.st Fri, 23 Jan 2026 08
- Context Therapeutics' (CNTX) Buy Rating Reiterated at D. Boral Capital - MarketBeat ue, 24 Mar 2026 07
- Context Therapeutics Adopts Shareholder-Friendly Board Governance Changes - tipranks.com Fri, 13 Mar 2026 07
- With $66M left, Context targets 2 cancer trial updates in 2026 - Stock Titan Mon, 23 Mar 2026 07
- Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from Guggenheim - MarketBeat ue, 24 Mar 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
39.70
+32.68%
|
29.92
+19.35%
|
25.07
+68.49%
|
14.88
|
| Research And Development |
|
31.86
+40.33%
|
22.70
+27.66%
|
17.78
+150.77%
|
7.09
|
| Selling General And Administration |
|
7.85
+8.64%
|
7.22
-0.92%
|
7.29
-6.42%
|
7.79
|
| General And Administrative Expense |
|
7.85
+8.64%
|
7.22
-0.92%
|
7.29
-6.42%
|
7.79
|
| Other Gand A |
|
7.85
+8.64%
|
7.22
-0.92%
|
7.29
-6.42%
|
7.79
|
| Total Expenses |
|
39.70
+32.68%
|
29.92
+19.35%
|
25.07
+68.49%
|
14.88
|
| Operating Income |
|
-39.70
-32.68%
|
-29.92
-19.35%
|
-25.07
-68.49%
|
-14.88
|
| Total Operating Income As Reported |
|
-39.70
-32.68%
|
-29.92
-19.35%
|
-25.07
-63.01%
|
-15.38
|
| EBITDA |
|
-39.69
-32.67%
|
-29.91
-19.36%
|
-25.06
-68.51%
|
-14.87
|
| Normalized EBITDA |
|
-39.69
-32.67%
|
-29.91
-19.36%
|
-25.06
-74.37%
|
-14.37
|
| Reconciled Depreciation |
|
0.02
+49.35%
|
0.01
-9.66%
|
0.01
+29.95%
|
0.01
|
| EBIT |
|
-39.70
-32.68%
|
-29.92
-19.35%
|
-25.07
-68.49%
|
-14.88
|
| Total Unusual Items |
|
—
|
—
|
0.00
+100.00%
|
-0.50
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
0.00
+100.00%
|
-0.50
|
| Special Income Charges |
|
—
|
—
|
0.00
+100.00%
|
-0.50
|
| Other Special Charges |
|
—
|
—
|
—
|
0.50
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-36.12
-35.17%
|
-26.73
-11.52%
|
-23.96
-61.53%
|
-14.84
|
| Pretax Income |
|
-36.12
-35.17%
|
-26.73
-11.52%
|
-23.96
-61.53%
|
-14.84
|
| Net Non Operating Interest Income Expense |
|
3.38
+5.57%
|
3.20
+174.94%
|
1.16
+112.69%
|
0.55
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
—
|
| Net Interest Income |
|
3.38
+5.57%
|
3.20
+174.94%
|
1.16
+112.69%
|
0.55
|
| Interest Expense |
|
—
|
—
|
—
|
—
|
| Interest Income Non Operating |
|
3.38
+5.57%
|
3.20
+174.94%
|
1.16
+112.69%
|
0.55
|
| Interest Income |
|
3.38
+5.57%
|
3.20
+174.94%
|
1.16
+112.69%
|
0.55
|
| Other Income Expense |
|
0.20
+14138.59%
|
-0.00
+97.43%
|
-0.06
+88.93%
|
-0.50
|
| Other Non Operating Income Expenses |
|
0.20
+14138.59%
|
-0.00
+97.43%
|
-0.06
-2672.95%
|
-0.00
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-36.12
-35.17%
|
-26.73
-11.52%
|
-23.96
-61.53%
|
-14.84
|
| Net Income From Continuing Operation Net Minority Interest |
|
-36.12
-35.17%
|
-26.73
-11.52%
|
-23.96
-61.53%
|
-14.84
|
| Net Income From Continuing And Discontinued Operation |
|
-36.12
-35.17%
|
-26.73
-11.52%
|
-23.96
-61.53%
|
-14.84
|
| Net Income Continuous Operations |
|
-36.12
-35.17%
|
-26.73
-11.52%
|
-23.96
-61.53%
|
-14.84
|
| Normalized Income |
|
-36.12
-35.17%
|
-26.73
-11.52%
|
-23.96
-67.16%
|
-14.34
|
| Net Income Common Stockholders |
|
-36.12
-35.17%
|
-26.73
-11.52%
|
-23.96
-61.53%
|
-14.84
|
| Diluted EPS |
|
-0.38
+17.39%
|
-0.46
+69.33%
|
-1.50
-61.29%
|
-0.93
|
| Basic EPS |
|
-0.38
+17.39%
|
-0.46
+69.33%
|
-1.50
-61.29%
|
-0.93
|
| Basic Average Shares |
|
95.19
+62.94%
|
58.42
+265.88%
|
15.97
+0.00%
|
15.97
|
| Diluted Average Shares |
|
95.19
+62.94%
|
58.42
+265.88%
|
15.97
+0.00%
|
15.97
|
| Diluted NI Availto Com Stockholders |
|
-36.12
-35.17%
|
-26.73
-11.52%
|
-23.96
-61.53%
|
-14.84
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
16.06
|
| Current Assets |
|
16.05
|
| Cash Cash Equivalents And Short Term Investments |
|
14.45
|
| Cash And Cash Equivalents |
|
14.45
|
| Prepaid Assets |
|
—
|
| Other Current Assets |
|
1.60
|
| Total Non Current Assets |
|
0.02
|
| Net PPE |
|
0.02
|
| Gross PPE |
|
0.02
|
| Other Properties |
|
0.02
|
| Non Current Deferred Assets |
|
—
|
| Other Non Current Assets |
|
—
|
| Total Liabilities Net Minority Interest |
|
4.19
|
| Current Liabilities |
|
4.19
|
| Payables And Accrued Expenses |
|
3.53
|
| Payables |
|
2.38
|
| Accounts Payable |
|
2.38
|
| Current Accrued Expenses |
|
1.15
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.65
|
| Current Debt And Capital Lease Obligation |
|
—
|
| Current Capital Lease Obligation |
|
0.00
|
| Other Current Liabilities |
|
0.01
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
|
| Long Term Capital Lease Obligation |
|
0.00
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
11.87
|
| Common Stock Equity |
|
11.87
|
| Capital Stock |
|
0.02
|
| Common Stock |
|
0.02
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
15.97
|
| Ordinary Shares Number |
|
15.97
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
79.91
|
| Retained Earnings |
|
-68.05
|
| Total Equity Gross Minority Interest |
|
11.87
|
| Total Capitalization |
|
11.87
|
| Working Capital |
|
11.86
|
| Invested Capital |
|
11.87
|
| Total Debt |
|
0.00
|
| Capital Lease Obligations |
|
0.00
|
| Net Tangible Assets |
|
11.87
|
| Tangible Book Value |
|
11.87
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-26.39
-81.26%
|
-14.56
+30.84%
|
-21.05
-55.34%
|
-13.55
|
| Cash Flow From Continuing Operating Activities |
|
-26.39
-81.26%
|
-14.56
+30.84%
|
-21.05
-55.34%
|
-13.55
|
| Net Income From Continuing Operations |
|
-36.12
-35.17%
|
-26.73
-11.52%
|
-23.96
-61.53%
|
-14.84
|
| Depreciation Amortization Depletion |
|
0.02
+49.35%
|
0.01
-9.66%
|
0.01
+29.95%
|
0.01
|
| Depreciation And Amortization |
|
0.02
+49.35%
|
0.01
-9.66%
|
0.01
+29.95%
|
0.01
|
| Other Non Cash Items |
|
2.00
-86.44%
|
14.75
|
—
|
0.50
|
| Stock Based Compensation |
|
1.33
+58.11%
|
0.84
-21.82%
|
1.08
+10.28%
|
0.98
|
| Operating Gains Losses |
|
0.11
+159.21%
|
0.04
-19.52%
|
0.05
-33.82%
|
0.08
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
0.11
+159.21%
|
0.04
-19.52%
|
0.05
-33.82%
|
0.08
|
| Change In Working Capital |
|
6.28
+280.74%
|
-3.48
-295.75%
|
1.78
+739.84%
|
-0.28
|
| Change In Prepaid Assets |
|
1.11
+159.27%
|
-1.87
-346.27%
|
0.76
+203.09%
|
-0.74
|
| Change In Payables And Accrued Expense |
|
5.28
+437.33%
|
-1.57
-250.68%
|
1.04
+83.39%
|
0.57
|
| Change In Accrued Expense |
|
4.19
+775.44%
|
-0.62
-52.10%
|
-0.41
-130.08%
|
1.35
|
| Change In Payable |
|
1.10
+215.84%
|
-0.95
-165.40%
|
1.45
+283.61%
|
-0.79
|
| Change In Account Payable |
|
1.10
+215.84%
|
-0.95
-165.40%
|
1.45
+283.61%
|
-0.79
|
| Change In Other Current Assets |
|
—
|
0.00
-100.00%
|
0.03
+200.00%
|
-0.03
|
| Change In Other Current Liabilities |
|
-0.11
-160.11%
|
-0.04
+25.09%
|
-0.06
+26.96%
|
-0.08
|
| Investing Cash Flow |
|
-2.03
+86.22%
|
-14.76
|
0.00
+100.00%
|
-0.54
|
| Cash Flow From Continuing Investing Activities |
|
-2.03
+86.22%
|
-14.76
|
0.00
+100.00%
|
-0.54
|
| Net PPE Purchase And Sale |
|
-0.03
-364.02%
|
-0.01
|
0.00
+100.00%
|
-0.04
|
| Purchase Of PPE |
|
-0.03
-364.02%
|
-0.01
|
0.00
+100.00%
|
-0.04
|
| Capital Expenditure |
|
-2.03
+86.22%
|
-14.76
|
—
|
-0.54
|
| Net Intangibles Purchase And Sale |
|
-2.00
+86.44%
|
-14.75
|
0.00
+100.00%
|
-0.50
|
| Purchase Of Intangibles |
|
-2.00
+86.44%
|
-14.75
|
0.00
+100.00%
|
-0.50
|
| Financing Cash Flow |
|
-0.02
-100.01%
|
109.29
|
0.00
+100.00%
|
-0.10
|
| Cash Flow From Continuing Financing Activities |
|
-0.02
-100.01%
|
109.29
|
0.00
+100.00%
|
-0.10
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
109.29
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
-0.02
|
—
|
—
|
-0.10
|
| Changes In Cash |
|
-28.43
-135.55%
|
79.98
+480.00%
|
-21.05
-48.35%
|
-14.19
|
| Beginning Cash Position |
|
94.43
+553.50%
|
14.45
-59.29%
|
35.50
-28.56%
|
49.69
|
| End Cash Position |
|
66.00
-30.11%
|
94.43
+553.50%
|
14.45
-59.29%
|
35.50
|
| Free Cash Flow |
|
-28.42
+3.05%
|
-29.31
-39.27%
|
-21.05
-49.42%
|
-14.09
|
| Common Stock Issuance |
|
0.00
-100.00%
|
109.29
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
109.29
|
0.00
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-02 View
- 8-K2026-03-23 View
- 10-K2026-03-23 View
- 8-K2026-03-13 View
- 8-K2026-02-27 View
- 42026-02-23 View
- 42026-02-23 View
- 42026-02-23 View
- 42026-02-23 View
- 8-K2026-01-08 View
- 8-K2025-11-05 View
- 10-Q2025-11-05 View
- 8-K2025-10-24 View
- 8-K2025-10-20 View
- 8-K2025-09-02 View
- 10-Q2025-08-06 View
- 42025-06-12 View
- 42025-06-12 View
- 42025-06-12 View
- 42025-06-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|